See more : Dongyue Group Limited (0189.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Apogee Therapeutics, Inc. (APGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apogee Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FS KKR Capital Corp. (FSK) Income Statement Analysis – Financial Results
- DLSI (ALDLS.PA) Income Statement Analysis – Financial Results
- Karora Resources Inc. (KRRGF) Income Statement Analysis – Financial Results
- Crixus BH3 Acquisition Company (BHACU) Income Statement Analysis – Financial Results
- TomTom N.V. (TMO.SW) Income Statement Analysis – Financial Results
Apogee Therapeutics, Inc. (APGE)
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 68.42M | 27.79M |
| General & Administrative | 24.58M | 2.94M |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 24.58M | 2.94M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 93.00M | 30.73M |
| Cost & Expenses | 93.00M | 30.73M |
| Interest Income | 9.02M | 92.00K |
| Interest Expense | 0.00 | 9.15M |
| Depreciation & Amortization | 9.02M | 33.52M |
| EBITDA | -83.99M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -93.00M | -30.73M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.02M | -9.06M |
| Income Before Tax | -83.99M | -39.79M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -33.52K |
| Net Income | -83.99M | -39.79M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -3.36 | -0.79 |
| EPS Diluted | -3.36 | -0.79 |
| Weighted Avg Shares Out | 25.01M | 50.67M |
| Weighted Avg Shares Out (Dil) | 25.01M | 50.67M |
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and...
Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement
Apogee Therapeutics, Inc. positive interim results achieved from Phase 1 study of APG777 for Atopic Dermatitis and Phase 2 study initiation and additional data expected in 1st half of 2024 and 2025, respectively. Company has potential to overcome other biologic drug...
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and...
Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. APG777's efficacy and safety profiles justify Phase 2 trials, aiming to outperform competitors like Sanofi's Dupixent by offering less frequent dosing....
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to potential for improved clinical responses in induction than currently available biologic therapies and the...
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and maintenance dosing of every 3- or 6-months
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I)...
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and...
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial PK and safety data from healthy volunteers expected mid-2024; on track to begin Phase 2 in moderate-to-severe atopic dermatitis in...
Source: https://incomestatements.info
Category: Stock Reports